MIC current news
Established in 1980, the MIC has answered over 200 000 queries from health care workers and we’ve done it well. During this time, the centre has been funded by a range of generous funders. Our current funding, kind favour of the Global Fund and Western Cape Department of Health ends in March 2019, so we’re on the hunt for more generous funders. Please, if you are one of those, or you know of anyone/any organisation that is, let us know.
It’s hard to believe that we’ve been running the hotline for ten years, but we have. And we’re very proud of the work we do and look forward to many more years of doing it.
The FDA is requiring the addition of a new warning to the lamotrigine prescribing information of a rare, but very serious adverse reaction called hemophagocytic lymphohistiocytosis (HLH).
The updated ‘National Malaria Treatment Guidelines 2017’ (final draft version) can be accessed on the NICD website (www.nicd.ac.za).
Early data from a study in Botswana has shown an increased risk in neural tube defects in babies born to mothers taking dolutegravir during pregnancy, prompting worldwide warnings against its use in pregnancy and women of child-bearing age.
Ning and colleagues recently published their research in the Journal of Psychopharmacology. Their study looked at reducing the dose of olanzapine or risperidone in stable schizophrenic patients and the effect on cognitive function and symptoms.
An article in the February Lancet discussed lessons learnt from eleven countries that are moving toward universal health coverage (UHC). An interesting read, as South Africa negotiates a National Health Insurance system.
Prescription drugs were previously assigned pregnancy categories A, B, C, D and X, which essentially over-simplified the issue. These categories will now be replaced with three detailed sub-sections that describe risks in a real world context.
In March 2013 the UK Medicines and Healthcare Products Regulatory Agency conducted a review of published literature on the benefits and risks of aqueous cream, especially when used for children with eczema. Both the NICE paediatric guidelines and the British National Eczema Society report that aqueous cream as a leave-on emollient (but not when used as a soap substitute) may cause stinging, itching, burning or redness. This was based on an audit of 100 children attending a dermatology clinic conducted by Cork MJ et al.
Over the past few months, two incidents of preventable mediation errors were noted. We can all learn from such occurrences and make sure that our places of work have sensible systems that attempt to minimise such occurrences. Here we report on the cases.